IVTECH SRL

Their core work

IVTECH is an Italian SME that develops advanced multiwell cell-culture systems designed to replicate physiologically relevant conditions for in-vitro testing. Their flagship product, Multidyn, is a low-cost bioreactor platform that enables researchers to grow and study tissue models outside the body. More recently, they have applied this platform expertise to cardiac 3D tissue models used for assessing the toxicity of chemical mixtures, bridging the gap between laboratory cell culture and regulatory safety testing.

What they specialise in

How they've shifted over time

IVTECH's early H2020 work (2015) spanned microactuator hardware development (MICACT) and their own patented cell-culture platform (Multidyn), suggesting a company building its core technology base. By 2021, their focus shifted decisively toward biological applications — specifically cardiac 3D tissue models, multi-omics analysis (proteomics, metabolomics, transcriptomics), and in silico modeling for toxicity testing. This evolution shows a classic SME trajectory: from hardware/platform development to domain-specific biological applications with regulatory relevance.

IVTECH is moving toward regulatory-grade in-vitro testing platforms, positioning themselves at the intersection of organ-on-chip technology and chemical safety assessment — a growing market driven by EU restrictions on animal testing.

How they like to work

IVTECH primarily joins projects as a technology partner rather than leading them, having coordinated only one project (the SME Phase 1 feasibility study for their own product). Despite being a small company with just 3 projects, they have built a remarkably broad network of 33 partners across 18 countries, indicating they are valued as a specialist contributor in large research consortia. Their willingness to participate in diverse consortia suggests they are flexible collaborators who bring specific hardware and platform expertise to larger teams.

Despite their small size, IVTECH has collaborated with 33 unique partners across 18 countries — an unusually wide network for an SME with only 3 projects, reflecting the large consortium format of the ALTERNATIVE project and their MSCA training network participation.

What sets them apart

IVTECH occupies a niche as an SME that both manufactures cell-culture hardware and understands the biological applications it enables. Their patented Multidyn platform gives them a concrete product — not just research capability — which makes them a practical partner who can supply technology, not just expertise. For consortium builders, they offer a rare combination: a small, agile company with real IP in bioreactor systems that can be adapted to specific tissue models and testing needs.

Highlights from their portfolio

• Multidyn
  IVTECH's own SME Phase 1 project to commercialize their patented multiwell cell-culture system — reveals their core product and business identity.
• ALTERNATIVE
  Their largest project (EUR 306,750) applying cardiac tissue models to chemical toxicity testing, marking their strategic pivot toward regulatory-relevant biological applications.